newsfilter
← Latest News
GlobeNewswire·

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to